Ovata Capital Management’s Celularity CELU Stock Holding History

Ovata Capital Management’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-70	Closed	-$6K	–	70
2022 Q1	$6K	Buy	+70	New	+$4.2K	﹤0.01%	131

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Palantir Technologies Aventura, Florida $9.72M AUM 6.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LDFO

Louis-Dreyfus Family Office Wilton, Connecticut $64.7M AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ovata Capital Management's CELU Position: Q2 2022 in Review

Ovata Capital Management sold out of Celularity (CELU) in Q2 2022, closing a stake of 70 shares — an estimated $6K sold.

Ovata Capital Management first reported a position in CELU in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 66 funds tracked by Wall St. Rank hold CELU as of Q2 2022.

Ovata Capital Management reported no remaining Celularity position as of Q2 2022 after selling out during the quarter.
Ovata Capital Management sold 70 Celularity shares in Q2 2022, an estimated $6K.
Ovata Capital Management first reported a position in Celularity in Q1 2022 and held it in 1 quarter.
Ovata Capital Management's Celularity position peaked at $6K in Q1 2022.
66 funds tracked by Wall St. Rank held Celularity as of Q2 2022.

Based on Ovata Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.